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Bax mutations in cell lines derived from hematological malignancies
JPP Meijerink, TFCM Smetsers, AW  Slöetjes, EHP Linders and EJBM Mensink
Department of Hematology, Molecular Hemato-Oncology Unit, University Hospital 'St Radboud' Nijmegen, The Netherlands
Many genes are Involved in cell cycle control, DNA repair and 
induction of cell death. Alterations in these genes have been 
responsible for the development of cancer as well as for resist­
ance to cancer therapy. Recently, an emerging family of bc/2- 
like genes has been identified that plays a role In the regulation 
of cell death. Its members are highly conserved in several 
domains which have been shown to be important for homodi- 
merization or heterodimerization. The ratio between BAX/BCL2 
heterodimers and BAX/BAX homodimers appears to be pivotal 
in deciding the life or death of a ceil. We recently detected 
mutations in evolutionary highly conserved domains of the bax 
gene In cell lines derived from hematologic malignancies. Simi­
lar artificially generated mutations in other bc!2-like family 
members bc!2, bcixl, or ced9 have been shown to alter their 
function. This suggests a role for bax mutations in the multi- 
step pathogenesis of hematological malignancies.
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Introduction
Cell proliferation and cell death are two important processes 
involved in embryonal development, tissue homeostasis and 
regeneration. One of the genes involved in the regulation of 
cell death is the human bcl2 gene, which can protect against 
cell death induced by a variety of death signals.1,2 Recently, 
an emerging family of related proteins has been identified.3 
The protein products of bcl2r] bclxl, 4  me//5 can protect 
against apoptosis whereas the protein products bax,6 bclxsf 
bacF and bak^~10 make cells more sensitive for apoptosis 
induction. The regulation of the cell death pathway by the 
bcl2-\\ke family members is very conserved throughout evol­
ution. The human bcl2 gene can partially substitute for ced9 
in nematode Caenorhabditis elegans in preventing develop­
mental cell death in ced9 loss-of-function mutants.11
The different members of the bcl2-like family can form 
homodimers or heterodimers with other members of the same 
family, possibly in a head-to-tail configuration.12 Three con­
served domains, box 1 to 3 as defined by Hengartner and Hor- 
vitz/1 seem to be important for dimerization. Mutation analy­
sis of the two C-terminal homology domains, called bcl2 
homology domain 1 (BH1, which equals box 2) and BH2 
(which equals box 3), demonstrates that several amino acid 
residues are crucial for dimerization.13 For bc!2 and bax it has 
been demonstrated that their protein ratio determines the cells 
susceptibility for cell death following a death signal. BAX/BAX 
homodimers renders a ceil more vulnerable for apoptosis and 
BCL2/BAX heterodimers provides protection.6,13 The model is 
more complex: first, the bax gene encodes for several protein 
products of which BAXa and BAX(3 seem to be the most 
important ones. BAXa is a membrane-bound protein whereas 
BAX|3 is a cytoplasmic protein.6 Second, other family mem­
bers are also involved and complex interactions among these 
proteins may dictate complex set points unique to each cell.14 
Third, most family members are also expressed in a tissue-
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specific manner, like bcix which seems to be predominantly 
expressed in neurons and thymocytes.4 Fourth, expression pat­
terns of specific family members can be modulated by exter­
nal signals,15 and therefore affect the specific set point within 
target cells.
Upon genotoxic stress, an intracellular defense program is 
activated to facilitate repair prior to distribution of mutations 
over daughter cells. This damage response pathway is regu­
lated by the p53-gene.16'17 Upon sustaining damage by 
chemotherapeutic agents or y-radiation, the p53 expression is 
upregulated by a post-transcriptional mechanism and immedi­
ately blocks the cell cycle at the G1 to S phase transition16 
and facilitates repair. For this, the p53 gene upregulates the 
expression of the wafl/cipl genelu and the gadd45 gene.19 If 
DNA damage is too severe, P53 can induce cell death.20
Induction of apoptosis in a p53-dependent pathway is regu­
lated by members of the bc/2-like family. P53-induced 
apoptosis is preceded by a decrease of bcl2 gene expression 
and an increase of bax gene expression.21,22 The P53 protein 
can directly modulate bcl2 and bax expression by a c/s-acting 
p53 negative response element located in the 5' untranslated 
region of the bcl2 gene23 and a p53 binding-site located in 
the promotor region of the bax gene.24
inactivation of the p53-dependent cell death pathway can 
contribute to resistance to therapy as well as to oncogenesis 
itself. In nearly all human neoplasms, mutations have been 
found in the p53 gene with concomitant loss of the normal 
allele.-25,26 Germ-line muations in the p53 tumor suppressor 
gene as found in families with Li-Fraumeni syndrome have 
been associated with increased risk for cancer development27 
Mutations in the p53 gene result in loss of the tumor sup­
pressor activity and enhancement of oncogenic activity by 
dimerization of mutant P53 with wild-type P53 to form an 
inactive dimer or tetramer.20 This lowers the DNA binding 
capacity of the P53 complex to target genes and subsequent 
transcriptional activation.29 In vivo experiments as well as cor­
relative studies have shown that mutations in the p53 gene 
also contribute to resistance to treatment.17'30,31
Deregulation of downstream genes in the p53-dependent 
cell death pathway can also contribute to oncogenesis and 
increased resistance to treatment. In many cases of human 
follicular lymphoma, the bcl2 gene is overexpressed due to a 
translocational event. As an effect of bcl2 overexpression, 
cells become less sensitive for induction of apoptosis and 
therefore have a longer lifespan with a simultaneous increased 
risk for the accumulation of secondary mutations.1 In mice, 
overexpression of bcl2 results in the expansion of a polyclonal 
B cell compartment, which occasionally dedifferentiates into 
a high-grade monoclonal disease in which the c-myc gene is 
frequently rearranged.32 Overexpression of bcl2 has also been 
correlated with poor prognosis to therapy in patients with non- 
Hodgkin's lymphoma, acute myeloid leukemia and prostate 
cancer.2 Since BCL2 and BAX have opposite effects on induc­
tion of apoptosis following a death signal, it seems reasonable 
that mutations which disturb BAX function exert a similar 
effect on cells as BCL2 overexpression. This way, aberrations 
in the bax gene could be involved in the genesis of cancer. U
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also seems likely that these mutations contribute to enhanced 
resistance to chemotherapy.
In this report we describe the presence of in vivo bax 
mutations in cell lines derived from hematological malig­
nancies. The frequency of the mutations is relatively high in 
the small number of cell lines tested. The potential role 
of these mutations in the pathogenesis of malignancies is 
discussed.
Materials and methods
Cell lines
Cell lines of different hematopoietic background were used in 
the present study and include three human T-ALL cell lines: 
CEM, Jurkat and HPB-ALL, a human Burkitt lymphoma cell 
line Daudi, and two human B cell lines JM and KM3.
RNA-isolation
RNA was isolated according to a method developed by 
Chirgwin et a/.33
Oligonucleotides
Sense oligonucleotides used were bax-exon 3 :5 ' GTCCAC- 
CAACAAGCTGAGCC 3', bax-exon 4: 5' GCCCTTTT- 
CTACTTTGCCAGC 3'; Antisense oligonucleotides used were: 
bax-exon 5: 5' TCCAGCCCAACAGCCGCTC 3'; bax- 
intron 5.2: 5' GACACGTAAGGAAAACGCATTAT 3'; bax- 
exon 6: 5' GCACTCCCGCCACAAAGATG 3; bax-exon 6,2: 
5' TCAGCCCATCTTCTTCCAGAT 3'. The C-terminal coding 
region of baxa or bax/3 cDNA was amplified using bax-exon 3 
primer in combination with bax-exon 6.2 primer or bax- 
intron 5.2 primer, respectively.
RT-PCR amplification
One microgram of total RNA was reverse transcripted in 
the presence of 40 mM Tris-HCl (pH 8.3), 75 itim KCI, 
3 mM MgCl2, 10 mM DTT, 625 ¿¿M of dATP, dTTP, dCTP and 
dGTP, 5 |xg/ml oligo dT, 1000 U/mi RNase inhibitor RNasin 
(Promega, Madison, Wl, USA), 10000 U/ml Moloney murine 
leukemia virus reverse transcriptase (MMLV-RT) (Gibco BRL, 
Gaithersburg, MD, USA) in a total volume of 20 jjlI. Reactions 
were overlaid with 60 jxl mineral oil (Sigma, St Louis, MO, 
USA), and were subsequently incubated at 20° C for 10 min, 
at 42° C for 45 min and at 95° C for 10 min, Samples were 
amplified by polymerase chain reaction (PCR) in a DNA ther­
mal cycler (Perkin Elmer Cetus, Norwalk, CT, USA), in the 
presence of 0.001% gelatine, 65 mM KCI, 28 mM Tris-HCl 
(pH 8.3), 2.6 mM MgCI2, 500 jxM of dATP, dTTP, dCTP and 
dGTP, 300 pmol/ml of oligonucleotides, and 25 U/m! Taq 
DNA polymerase (Gibco BRL) in a total volume of 100 fxl. 
Amplification started with an initial denaturation step at 94° C 
for 5 min, followed by 30 cycles at 94° C for 1.5 min, 59° C 
for 2 min and 72° C for 2 min. After the last cycle, extension 
phase was prolonged for 10 min at 72° C, and the reactions 
were cooled to 40° C.
Sequencing
PCR products were sequenced according to the method 
developed by Innis et a/,34 with minor modifications, Baxa. 
PCR product was sequenced using oligonucleotides bax- 
exon 4, bax-exon 5 or bax-exon 6, BaxfB PCR product was 
sequenced using oligonucleotides bax-exon 4, bax-exon 5 or 
bax-exon 6, Sax/3 PCR product was sequenced using oligo­
nucleotides bax-exon 4, bax-exon 5 bax-intron 5,
Antibodies
Bcl2 antibody 124 (Dako, Glostrup, Denmark) was a mouse 
IgGI, kappa. Bax antiserum P-19 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) is a polyclonal rabbit antiserum raised 
to a peptide corresponding to amino acids 43-61 of the 
mouse bax gene, but also reacts with human bax. Horseradish 
peroxidase conjugated goat anti-mouse IgGI (Southern 
Biotechnology Association, Birmingham, AL, USA) and per­
oxidase-conjugated goat anti-rabbit (Jackson Immuno 
Research, West Grove, Ml, USA) were used as secondary anti­
bodies.
SDS PAGE and immunoblotting procedure
Cells were washed once with phosphate-buffered saline (PBS) 
and resuspended at a concentration of 2 X 107 cells/ml in 
PBS, Cells were boiled after addition of 2 X SDS sample 
buffer. One micro I iter of these extracts was applied to a 12.5% 
polyacrylamide gel using the fast system (Pharmacia, Uppsala, 
Sweden). After electrophoresis the samples were blotted by 
diffusion for 1 h at 60° C onto a 0.45 jim nitro-cellulose mem­
brane (Schleicher and Schuell, Dassel, Germany) in blotting 
buffer (25 mM Tris, 192 mM glycine (pH 8.3), 20% methanol). 
Blocking buffer for immunological detection was prepared by 
heating 0.5% NIP 552 blocking reagent (Amersham, Bucks, 
UK) for 1 h at 65° C. Blocking buffer was cleared by centrifug­
ation and Tween-20 was added to a final concentration of
0.05%. The membrane was blocked for 1 h at room tempera­
ture (RT) in blocking buffer. The first antiserum was added to 
a final concentration of 2 |xg/ml. The membrane was washed 
three times in PBS containing 0.05% Tween-20 and incubated 
for 1 h at RT in 3000-fold diluted secondary antibody in 
blocking buffer. After five washes with PBS containing 0.05% 
Tween-20, blots were developed using the ECL detection sys­
tem (Amersham) and used for exposure on an X-ray film.
Results and discussion
mRNA of six hematopoietic cell lines were screened for 
mutations in the bax gene by an RT-PCR strategy. W e focussed 
on the C-termina! coding region of the bax gene in which the 
BH1 and BH2 domains are located, important for heterocli- 
merization of BAX with BCL2 or BCLXL.7'13 The region con­
taining the N-terminal homology domain Box 111 was not 
screened, although this region may also be important for 
dimerization of bcl2-like family members.12 We found three 
mutations in two out of six cell lines (33%). Since we did 
not check the N-terminal coding region of the bax gene, the 
frequency may be underestimated.
Cell line HPB-ALL, which was derived from a patient with 
T cell acute lymphoblastic leukemia (T-ALL), expressed bax
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mRNA in which a G to A mutation (not shown) was present 
at position 199 (relative to the ATG start codon) as well as the 
normal allele. This mutation leads to the substitution of a gly­
cine residue by an arginine residue (G67R). Alignment of this 
region to other bcl2~like family members (Figure 1a) demon­
strates that this glycine residue is very conserved throughout 
evolution. This domain is located between the conserved 
Box 1 and Box 2 regions,11 and the functional significance of 
this region has not been determined. A second C to T mutation 
was present in intron 5 at position 508 (not shown) in the 
same cell line. The unmutated allele was also expressed on 
mRNA level. Since this intron is alternatively spliced, this 
mutation only affects the BAX|3 variant,6 By this mutation an 
arginine residue is sustituted by a cysteine residue. It is not 
known ¡f expression of BAX(3 like BAXa renders a cell more 
vulnerable for induction of cell death, and therefore it is diffi­
cult to draw any conclusion regarding this mutation. It is not 
known if both mutations occur in the same allele.
The Burkitt lymphoma ceil line Daudi, expressed bax 
mRNA containing a G to T mutation in BH1 on position 323, 
but also expressed the normal allele (Figure 2). By this 
mutation, a glycine residue is substituted by a valine residue. 
This BAX G108V mutation is located in BH 1 '3 (also defined 
as Box 211) at a position which is completely conserved in all 
known 6c/2-like family members (Figure lb)* Mutation analy­
sis for the bc\2 gene13 and the bcfxl gene7 clearly demon­
strates that substitution of this particular glycine residue by 
glutamate or alanine, respectively, results in complete loss of 
heterodimerization capacity with BAX and concomitant loss 
of cell death repressor function. In another mutation analysis, 
the nematode C. elegans paradoxically demonstrates a gain-
of-function of CED9 upon substitution of the same glycine 
residue by glutamate. Although BCL2 normally can substitute 
for CED9 in C. elegans,u this mutation renders BCL2 com­
pletely ineffective for rescue of CED9 I oss-of-f unction 
mutations. Interestingly, the bcl2 gene isolated from a chicken 
B cell lymphoma cDNA bank coded for a valine instead of a 
glycine residue at the same position,35 and it was speculated 
that this mutation contributed to lymphoma genesis.36 Mutat­
ing this glycine residue has not only different effects in differ­
ent proteins of the bc/2-like family members, but its effect is 
also dependent on the nature of the amino acid substitution.
What are the consequences of mutations within the bax 
gene? We hypothesize that the mutation in the bax gene as 
found in the cell line Daudi is accompanied with a loss-of- 
function of BAX, since gain-of-function would lead to a dra­
matic increase of cell death. The protein data also argue in 
favor of this suggestion (Figure 3). Normal bone marrow cells 
as well as the cell lines CEM, Jurkat, JM, HPB-ALL and KM3 ail 
express BAX as well as BCL2, although there are differences in 
the relative BAX/BCL2 ratio as measured by our assay. The 
situation is different in cell line Daudi, since we did not detect 
any BCL2 expression whereas BAX expression seems to be 
abundant, Therefore, BAX homoclimers probably will be 
abundant as well, and this ceil line would be extremely sensi­
tive for apoptosis induction by normal BAX function which is 
not the case. It would be thrilling to know in what way these 
mutations affect BAX function. Do they make BAX oncogenic 
by more effective heterodimerization with BCL2 or BCLXL or 
by less effective homodomerization? Do they act in a domi­
nant negative way on the normal allele by BAX(mutan0/ 
BAX{wj|C|tvpe) homodimerization and concomitant loss-of-func-
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A
Figure! Alignment of bax gene domains which were mutated in cell lines HPB-ALL and Daudi with other bc/2-like family members, (a) 
alignment of C. elegans or G  briggsae CED9,11 chicken BCL2,39 mouse BCL2/0 human BCL2,41 human BAX,6 human BCLXs and BCLX1,4 
chicken BCLX/ MCL142 and BAK."* The BAX G67R mutation as found in cell line HPB-ALL is indicated by a triangle. The most conserved amino 
acid residues among the genes are indicated in bold (b) Alignment of the BH1 domain for bc/2-like genes as used in (a) supplemented with 
chicken BCL2*,35 mouse BAD,7 mouse A1,43 Epstein-Barr virus BHRF1 and African swine virus LMW5-HL.3 The BAX G108V mutation as found 
in cell line Daudi is indicated by a triangle. The most conserved amino acids are indicated in bold
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Figure 2 Sequence of the BH1 region of the bax gene from cell 
lines CEM and Daucli. The G to T mutation present in one of the bax 
alleles in the Daudi cell line results in the G108V mutation
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tion? Functional studies will be necessary to provide an 
answer.
The Daudi cell line is derived from a Burkitt lymphoma with 
a rearranged and overexpressed c-myc gene. Overexpression 
of c-myc induces apoptosis in fibroblasts under conditions 
which normally promote G1 arrest, and it was hypothesized 
that secondary defects in tumorigenesis affect the cell death 
pathway.37 It has been demonstrated that ectopic expression 
of bci-2 inhibits apoptosis induced by deregulated c-myc 
expression.38 Since BCL2 and BAX have opposite effects on 
the cells susceptibility to undergo cell death, it is clear that 
mutations which disrupt BAX function could contribute to 
Burkitt lymphoma genesis in an identical manner. This may 
have been the case in the patient from which the Daudi cell 
line is derived.
Overexpression of BCL2 as a first genetic defect seems to 
be sufficiently tumorigenic in mice model.32 Most human fol­
licular lymphoma cases carry the t(T4;18) in which the bcl2 
gene is deregulated. Therefore, it is important to investigate 
whether mutations in the bc/2-like family member bax also 
contribute to cancer development. Mutations in the p53 gene 
and defects in genes which are part of the p5J-dependent 
apoptotic machinery like bc!2 provide increased resistance to 
chemotherapeutic agents as well as y-radiation.2'17'26'30'31 It 
therefore seems reasonable that mutations negatively affecting 
BAX function also provide increased resistance to treatment.
In conclusion, we found mutations in the bax gene in about 
30% of the human hematological cell lines tested. Mutations 
in the conserved regions of the bax gene are probably associ­
ated with a loss-of-function of BAX, and may contribute as an 
oncogenic event to the pathogenesis of cancer as well as to 
increased resistance to treatment; so far these mutations have 
been found in hematological cell lines. In order to demon­
strate the frequency and importance of these mutations, it is 
necessary to screen a large panel of tumor samples derived 
from hematological malignancies as well as other types of 
cancer.
1831
a 1 2 3 4 5 6
36 KDa 
30 KDa
BCL2
b 1 2 3 4 5 6 7
30 KDa
BAX
Figure 3 BCL2 and BAX detection by an immunoblot of cell lysates from 1: normal bone marrow cells; 2: HPB-ALL; 3: Daudi; 4: KM3; 
5:CEM; 6: Jurkat; 7: JM. The immunoblot was consecutively screened for (a) BCL2 with moAb 124 (Dako) or (b) BAX with polyclonal P-19 
antiserum (Santa Cruz Biotechnology)
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